KBP 336
Alternative Names: KBP-336Latest Information Update: 06 Dec 2023
At a glance
- Originator KeyBioScience
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Amylin receptor agonists; Calcitonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 02 Oct 2023 Preclinical trials in Obesity in Denmark prior to October 2023 (SC)
- 02 Oct 2023 Preclinical trials in Type 1 diabetes mellitus in Denmark prior to October 2023 (SC)
- 02 Oct 2023 Pharmacodynamics data from preclinical trials in Type 1 diabetes mellitus and Obesity presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)